Advance stains IHC, ISH & if
Ended Purchase Order Awarded Last action
- Contract number
- W81K0021P0269
- Awardee
-
Roche Diagnostics Corporation UEI JDMDFEZBYH36
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $4,432,757
Award facts
- Opportunity
-
- Histology Testing, Brooke Army Medical Center, JBSA Fort Sam Houston - Texas Pre-Solicitation · W81K0021Q0049 · Posted May 18, 2021
- Contract value 73% obligated
-
- $4,432,756.73 Current, with exercised options
- $6,101,656.73 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 2 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Madison, MN 56256, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$625,893 | |
| Funding Only Action | -$81,046 | |
| Funding Only Action | -$817,004 | |
| Funding Only Action | $1,668,900 | |
| Exercise an Option | $0 | |
| Funding Only Action | -$718,900 | |
| Funding Only Action | $1,668,900 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Funding Only Action | $1,668,900 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $1,124,490 | |
| Funding Only Action | $544,410 | |
| Original award | $0 |
Show all 14
About this award
The Defense Health Agency awarded a $6.1 million firm fixed-price purchase order to Roche Diagnostics Corporation on October 1, 2021, for advanced histology staining services including immunohistochemistry, in-situ hybridization, and immunofluorescence testing. The contract supports Brooke Army Medical Center at Joint Base San Antonio Fort Sam Houston in Texas and operates on a cost-per-test model with an ultimate completion date of September 30, 2026. No set-aside designation was used in this competitive award. The underlying solicitation specified that all equipment and supplies must be FDA-approved and integrate with military healthcare information systems, including the Composite Health Care System and MHS Genesis electronic health record platform, while utilizing SQL 2016 database and Windows 2016 server software infrastructure.
Roche Diagnostics Corporation, a foreign-owned manufacturer of in vitro diagnostic products and reagents, is well-positioned as a prime contractor having established multiple significant federal contracts across the Department of Veterans Affairs and Defense Health Agency. The company's extensive portfolio demonstrates particular expertise in providing advanced diagnostic technologies and laboratory testing services to military and federal healthcare systems. This award reflects Roche's competitive standing in the federal marketplace and complements its existing landscape of histology-related contracts valued in the millions, positioning the company to deliver specialized laboratory diagnostic capabilities critical to military medical operations.
Quick answers
Who was awarded contract W81K0021P0269?
W81K0021P0269 was awarded to Roche Diagnostics Corporation by Medical Command (Department of the Army) on October 1, 2021.
How much is contract W81K0021P0269 worth?
The government has obligated $4,432,757 on W81K0021P0269. Its potential value, with all options, is $6,101,657.
Which agency awarded contract W81K0021P0269?
Medical Command (Department of the Army) awarded W81K0021P0269, with funding from Defense Health Agency (Department of Defense).
Was contract W81K0021P0269 competed?
The extent of competition for W81K0021P0269 was competed under sap. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award